- Alodokter’s revenue stagnated in 2022 but cost cuts halved losses.
- Operating expenses dropped, especially in staffing and marketing.
- However, negligible growth raises concerns despite new funding.
Alodokter, Indonesia’s leading healthtech platform, saw negligible 1% revenue growth in 2022 for parent firm Ranelagh. But losses halved thanks to major cost-cutting efforts.
Expenses dropping
While telemedicine subscriptions remained the top revenue driver, growth slowed. Advertising and one-off consultations rose but didn’t offset expenses falling across the board, especially in staffing, marketing and doctors.
Despite weaker financing cash inflows, reduced operating losses cut net cash burn by 56%.
However, Ranelagh’s auditor raised doubts about its ability to continue operating.
Stagnant growth continues to rise
Since then, Alodokter has shored up its position through new funding rounds, including $6M from Optima Health and $5.2M jointly from HL Mando and Beacon Venture Capital.
But 2022’s stagnant growth raises concerns.
You can also read the original story in its entirety on https://www.techinasia.com/alodokter-sees-stagnant-revenue-cuts-losses-2022
